Recombinant Adeno-Associated Virus Serotype 6 (rAAV2/6)-Mediated Gene Transfer to Nociceptive Neurons through Different Routes of Delivery
Open Access
- 1 January 2009
- journal article
- Published by SAGE Publications in Molecular Pain
- Vol. 5, 52
- https://doi.org/10.1186/1744-8069-5-52
Abstract
Gene transfer to nociceptive neurons of the dorsal root ganglia (DRG) is a promising approach to dissect mechanisms of pain in rodents and is a potential therapeutic strategy for the treatment of persistent pain disorders such as neuropathic pain. A number of studies have demonstrated transduction of DRG neurons using herpes simplex virus, adenovirus and more recently, adeno-associated virus (AAV). Recombinant AAV are currently the gene transfer vehicles of choice for the nervous system and have several advantages over other vectors, including stable and safe gene expression. We have explored the capacity of recombinant AAV serotype 6 (rAAV2/6) to deliver genes to DRG neurons and characterized the transduction of nociceptors through five different routes of administration in mice. Direct injection of rAAV2/6 expressing green fluorescent protein (eGFP) into the sciatic nerve resulted in transduction of up to 30% eGFP-positive cells of L4 DRG neurons in a dose dependent manner. More than 90% of transduced cells were small and medium sized neurons (< 700 microm 2), predominantly colocalized with markers of nociceptive neurons, and had eGFP-positive central terminal fibers in the superficial lamina of the spinal cord dorsal horn. The efficiency and profile of transduction was independent of mouse genetic background. Intrathecal administration of rAAV2/6 gave the highest level of transduction (approximately 60%) and had a similar size profile and colocalization with nociceptive neurons. Intrathecal administration also transduced DRG neurons at cervical and thoracic levels and resulted in comparable levels of transduction in a mouse model for neuropathic pain. Subcutaneous and intramuscular delivery resulted in low levels of transduction in the L4 DRG. Likewise, delivery via tail vein injection resulted in relatively few eGFP-positive cells within the DRG, however, this transduction was observed at all vertebral levels and corresponded to large non-nociceptive cell types. We have found that rAAV2/6 is an efficient vector to deliver transgenes to nociceptive neurons in mice. Furthermore, the characterization of the transduction profile may facilitate gene transfer studies to dissect mechanisms behind neuropathic pain.Keywords
This publication has 44 references indexed in Scilit:
- Pathological and protective roles of glia in chronic painNature Reviews Neuroscience, 2009
- Herpes Vector–mediated Gene Transfer in the Treatment of Chronic PainMolecular Therapy, 2009
- Phosphorylation Does Not Prompt, Nor Prevent, the Formation of -synuclein Toxic Species in a Rat Model of Parkinson's DiseaseHuman Molecular Genetics, 2008
- Efficient delivery of RNA Interference to peripheral neurons in vivo using herpes simplex virusNucleic Acids Research, 2008
- Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic painProceedings of the National Academy of Sciences, 2008
- Neonatal Intraperitoneal or Intravenous Injections of Recombinant Adeno-Associated Virus Type 8 Transduce Dorsal Root Ganglia and Lower Motor NeuronsHuman Gene Therapy, 2008
- An HSV vector system for selection of ligand-gated ion channel modulatorsNature Methods, 2007
- Remote Nerve Injection of Mu Opioid Receptor Adeno-associated Viral Vector Increases Antinociception of Intrathecal MorphineThe Journal of Pain, 2005
- HSV vector-delivery of GDNF in a rat model of PD: partial efficacy obscured by vector toxicityBrain Research, 2004
- Ethical guidelines for investigations of experimental pain in conscious animalsPAIN®, 1983